Entremed (ENMD)

[docaaron1]

How about urinary agiostatin as a biomarker for ENMD 2076 use.

ENMD 2076 appeared to work better in tumors with high P53 expression and agiostatin has been shown to increase P53 levels and angiostatin is a natural anti-agiogenic molecule associated with some tumors. Maybe high levels of urinary angiostatin found in a patient may indicate higher tumor angiostatin levels and P53 levels. Maybe urinary angiostatin biomarker could be added to the biomarker profile someday predicting ENMD 2076 chances of success.

Just a thought,
Aaron

“Within the TNBC subset itself, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and pro-apoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression. This information provides the basis for a predictive biomarker strategy to explore in future clinical trials with ENMD-2076.”

http://www.entremed.com/news/entremed-announces-publication-of-preclinical-results-for-enmd-2076-in-triple-negative-breast-cancer/

“Furthermore, [angiostatin] K1-3, K1-4 or K1-4.5 increased the expression of p53 protein and its downstream effectors, enhanced FasL-mediated signaling pathways, and decreased activation of AKT.”

http://www.ncbi.nlm.nih.gov/pubmed/16601838

“Levels of [angiostatin] AS are elevated in the urine of patients with [epithelial ovarian cancer] EOC and may be of diagnostic and/or prognostic clinical importance. Further studies of uAS as a biomarker for EOC alone or in combination with other markers are warranted.”

http://www.ncbi.nlm.nih.gov/pubmed/20071014